Voice of scientist
Talk series featuring discussions from our customers and leading experts in the pharmaceutical industry.
Join us as our customers share their profound knowledge and expertise on various topics related to mass spectrometry, providing invaluable insights and practical solutions.
The talks will be released throughout the year.
August
Birgitte Støvring, Scantox
Preparation of rodent whole blood and plasma microsamples for LC-MS/MS bioanalysis in toxicology studies
Microsampling analysis in TK and PK studies offers significant advantages, encompassing economic and ethical considerations that propel the research of novel and secure medications. Scantox delves into strategies to address potential constraints related to minimal sample volumes and sample homogeneity. By ensuring precise and accurate data, a validated method aligned with ICH M10 guidelines can be developed, fostering advancements in pharmaceutical research.
Jose Carlos Gonzalez, AMSbiopharma
Sphingolipid biomarkers in neurodegenerative drug development
Sphingolipid studies offer a convenient approach for biomarker analysis in neurodegenerative diseases, whether in vitro or in vivo. On this talk, AMSbiopharma discusses the unique method development and validation process to simultaneously analyze six sphingolipids, encompassing ceramides and sphingosines subfamilies through LC-MS.
October
Benjamin Smith, Cyprotex
Development of an LC-MS Method to Quantify Endogenous Urea in Mouse Plasma and BAL.
One challenge in BronchoAlveolar Lavage procedures is the fluctuating liquid volume collected, complicating drug quantification in studies. Adding to this complexity, Urea presents unique analytical challenges for LCMS analysis. Join the Cyprotex team to explore their innovative approach in tackling these obstacles. They have successfully completed 8 studies on this subject, showcasing a dependable method to address these issues.
John Perkins, KCAS
Optimization of extraction & LC-MS conditions for the bioanalysis of antibody drug conjugates with diverse chemistries
The success of ADCs bioanalysis hinges on a strategic combination of sensitive MS platforms and precise sample treatment. Understanding the challenges posed by molecule intricacies, such as the potential instability of ADCs affecting free payload assays, is crucial. The KCAS team has leveraged this insight to pioneer the development of reliable and robust Hybrid LC-MS/MS methods. These methods not only provide flexibility for ADC analysis but also serve as a viable alternative to traditional ligand binding approaches.
Davide Massari and Chiara Olmi, ERBC Group
Parallel setup of a series of micro LC methods, coupled with the low-resolution mass spec (API7500) for TG2 inhibitors
During the Drug Discovery phase, aligning with sponsors' timelines is crucial for success. Fast method optimization is key. On this presentation, the ERBC team demonstrated how to optimize and qualify 9 non-GLP methods. These methods support preliminary screening for selecting new candidates through TK evaluation. The team achieved this by combining microLC with the latest SCIEX triple quad technology.
Challenges in quantification of NDSRI´s
with Dama Venugopal Rao, PhD, MBA, Lead-Structural Characterisation and Analytical Expert- complex injectables at Dr. Reddy's Laboratories.
Discover the latest regulations on daily intake of nitrosamine and NDSRIs. Join Dr. Dama as he discusses managing impurities in API manufacturing using mass spectrometry.
Qualification of lipid biomarker assays
with Freddy Oosterbring, Senior Scientist Deputy Director Laborator at Ardena.
Explore how Freddy Oosterbring overcame challenges in sample volume for biomarker quantification using chromatography with triple-quad mass spectrometry.
Mass spectrometry in Alzheimer´s disease diagnosis
with Jose Antonio Allué, Senior Scientist Mass Spectrometry Laboratory, R&D Department at Araclon.
Join Dr. Allué in his 14-year journey working on Alzheimer's disease. Learn how ion mobility aids in validating markers and accelerating research to solve this critical disease.
Ultimate sensitivity with SCIEX 7500 system
with Ashwani Gaur, Senior Principal Scientist, Drug Metabolism and Pharmacokinetics at Syngene.
Join Ashwani Gaur in exploring Syngene's journey to bioanalytical excellence, highlighting the power of technology and human resources in achieving success.
Nitrosamine impurities in dermal products
with Emiliano de Dominicis, Chemistry Research Director at Mérieux NutriSciences.
Explore Emiliano's experience in quantifying nitrosamine and NDSRIs at low limits in dermal products. Discover their approach to complex matrices through analytical chemistry and mass spectrometry.
Extractables and leachables assessments in biologics manufacturing
with Lukas Mogler, Senior Group Leader, Extractables and Leachables at Lonza.
Learn from Lukas Mogler about the complexities of identifying and quantifying extractables and leachables in biologics manufacturing using various analytical techniques.
LC-MS for oligonucleotide characterization
with Margalida Esmeralda, responsible of IQS SCIEX Demo Lab at Instituto Químico de Sarrià IQS.
Dive into the world of oligonucleotides with Margalida and IQS. Explore the role of LC-MS in characterizing new biotherapeutics and addressing customer inquiries.
Parallel setup of a series of micro LC methods, coupled with the low-resolution mass spec (API7500) for TG2 inhibitors
with Davide Massari and Chiara Olmi, ERBC Group
During Drug Discovery, meeting sponsor timelines is essential. The ERBC team showed how to quickly optimize and qualify nine non-GLP methods for preliminary screening in TK evaluation, using microLC with the latest SCIEX triple quad technology.
Metabolomics: From target engagement to metabolic phenotyping. Applications in drug discovery
With Filippos Michopoulos, Astrazeneca
Explore the science of metabolic profiling technologies with Filippos Michopoulos from Astra Zeneca. Discover the key parameters essential for obtaining high-quality data in both target and untargeted (Data Independent Acquisition) metabolic profiles. Uncover how these parameters help in identifying new biomarkers and deepening our understanding of metabolomic adaptation and mechanisms of action.
Pathophysical subtypes of mild cognitive impairement due to Alzheimer's disease identified by CSF proteomics
with Bruno Manadas, CNC
Explore brain and neurodegenerative diseases present complex challenges, often necessitating diverse strategies and analytical methods to derive meaningful insights. Leveraging the proteomics LCMS proficiency within the Bruno Manadas team, a breakthrough emerged unveiling two distinct subtypes of AD patients during the MCI stage. This discovery holds crucial implications for shaping and deciphering clinical trials, hinting at a potential link between treatment efficacy and the particular AD subtype individuals are categorized under.